Speaker:                       David Rizzieri, M.D.

                                    Professor of Medicine

                                    Division of Hematologic Malignancies and Cellular Therapy

                                    Duke Medicine

Topic:                         Updates from IWCLL meeting 9/15: Moving to

           non-chemotherapy induction therapy for CLL

Date:                           Tuesday, October 6, 2015

Time:                          12:00 p.m. – 1:00 p.m.

Location:                    CR 9015 North Pavilion

Faculty (Speaker) Disclosure: David Rizzieri, MD, has indicated that he has the following relationships with industry to disclose:  Advisory Board Member and Speaker for Celgene;  Advisory Board Member and Consultant for Gilead; Advisory Board Member and Speaker for Incyte;  Expert Reviewer for Millennium;  Advisory Board Member and Consultant for Novartis;  Expert Reviewer for Pfizer;  Expert Reviewer and Consultant for Sanofi-Aventis;  Advisory Board Member and Speaker for Seattle Genetics;  and Advisory Board Member and Speaker for Spectrum.

Activity Medical Director/Planning Committee Disclosure(s):  Dr. Mitchell Horwitz discloses the following personal/financial relationships which are relevant to this activity:  Advisory Board Member for Genzyme; Principal Investigator for both Otsuka and Pfizer.

Accreditation: The Duke University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The Duke University School of Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)ä.  Physicians should only claim credit commensurate with the extent of their participation in the activity.

Unapproved Use Disclosure: Duke School of Medicine requires CME faculty (speakers) to disclose to the attendees: 1) When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and 2) Any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty at this symposium may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.  This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

You must text the six letter code provided by the speaker to (919)213-8033 to receive credit for attending this conference.